ArticleJournal of the American Academy of Dermatology2020
Malignancy in dermatomyositis: A retrospective study of 201 patients seen at the University of Pennsylvania.
Article in Journal of the American Academy of Dermatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 34 citations in OpenAlex.
- Paraneoplastic dermatomyositis with atypical features associated with a solid pseudopapillary pancreatic neoplasm.Clinical rheumatology · 2026Review
- Malignancy in Idiopathic Inflammatory Myopathies: Recent Insights.Clinical reviews in allergy & immunology · 2025Review
- Dermatomyositis: focus on cutaneous features, etiopathogenetic mechanisms and their implications for treatment.Seminars in immunopathology · 2025Review
- Risk, risk factors, and screening of malignancies in dermatomyositis: current status and future perspectives.Frontiers in oncology · 2025Review
- Amyopathic Dermatomyositis in a Patient With Breast Cancer in Remission: A Case Report and a Systematic Review of the Literature.Case reports in dermatological medicine · 2025Article
- Research progress on the dermatomyositis specific autoantibodies and malignancy associated dermatomyositis.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2023Article
- Features of MRI honeycomb edema signals in cancer-associated dermatomyositis patients: a brief report.Clinical rheumatology · 2023Article
- Comparison of characteristics and anti-MDA5 antibody distribution and effect between clinically amyopathic dermatomyositis and classic dermatomyositis: a retrospective case-control study.Frontiers in immunology · 2023Article
- Malignancy in dermatomyositis: a mono-centric retrospective study of 134 patients in China and a potential predictive model.Frontiers in medicine · 2023Article
- Treatment of gastric cancer with dermatomyositis as the initial symptom: Two case reports and review of literature.World journal of clinical cases · 2022Article
- Tumor markers are associated with rapidly progressive interstitial lung disease in adult-dermatomyositis.Clinical rheumatology · 2022Article
- Incidence of systemic autoimmune myopathies and their risk of cancer in Leeds, UK: an 11-year epidemiological study.Rheumatology advances in practice · 2022Article
- Prevalence of Nasopharyngeal Carcinoma in Patients with Dermatomyositis: A Systematic Review and Meta-Analysis.Cancers · 2021Review
- Dermatomyositis and malignancy: should all patients with dermatomyositis undergo malignancy screening?Annals of translational medicine · 2021Review
- Clinical Characteristics and Management of Patients With Clinical Amyopathic Dermatomyositis: A Retrospective Study of 64 Patients at a Tertiary Dermatology Department.Frontiers in medicine · 2021Article
- Secondary Causes of Myositis.Current treatment options in neurology · 2020Review
- Characteristics of Patients With Adult-Onset Dermatomyositis at 2 Tertiary Care Centres in Ontario, Canada.Journal of cutaneous medicine and surgeryArticle
Corrections and comments
- Commented on by
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is an increased incidence of malignancy in patients with dermatomyositis. It is unknown if the risk differs between the subtypes of dermatomyositis.
objectiveTo (1) compare the prevalence of malignancy-associated dermatomyositis between patients with classic and clinically amyopathic disease and (2) determine factors associated with an increased risk of malignancy-associated disease.
methodsRetrospective cohort study of 201 patients with adult-onset dermatomyositis prospectively enrolled in a longitudinal dermatomyositis database between July 2008 and April 2018 at an outpatient dermatology urban tertiary referral center. The main outcome measure was a diagnosis of malignancy, excluding nonmelanoma skin cancer.
resultsThere were 201 patients with adult-onset dermatomyositis: 142 (71%) classic and 59 (29%) clinically amyopathic. Within 2 years of diagnosis, the prevalences of malignancy-associated classic and clinically amyopathic dermatomyositis were 9.9% and 1.7%, respectively. In this time period, patients who were older at dermatomyositis diagnosis (P = .01) and had the classic subtype (P = .04) were significantly more likely to have an underlying malignancy on multivariable regression analysis. LIMITATIONS: This was a retrospective study of prospectively collected data at a single tertiary referral center.
conclusionOlder age and classic dermatomyositis are independent risk factors for malignancy-associated dermatomyositis within 2 years of disease onset.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.